Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2026-02-21 @ 9:03 AM
Study NCT ID:
NCT04095858
Status:
TERMINATED
Last Update Posted:
2023-02-08
First Post:
2019-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Sponsor:
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-01-05
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-11-05
Completion Date Type:
ACTUAL
First Submit Date:
2019-09-18
First Submit QC Date:
None
Study First Post Date:
2019-09-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-10-18
Results First Submit QC Date:
None
Results First Post Date:
2022-11-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-11
Last Update Post Date:
2023-02-08
Last Update Post Date Type:
ACTUAL